Fig. 7: Immune landscape and survival analysis based on SPRS in LUAD. | npj Precision Oncology

Fig. 7: Immune landscape and survival analysis based on SPRS in LUAD.

From: Integrative multi-omics and machine learning reveal critical functions of proliferating cells in prognosis and personalized treatment of lung adenocarcinoma

Fig. 7: Immune landscape and survival analysis based on SPRS in LUAD.The alternative text for this image may have been generated using AI.

a The distribution of TME immune cell type signatures between high- and low-SPRS patients in LUAD. b The distribution of immune suppression, immune exclusion, and immunotherapy-related signatures between high- and low-SPRS patients in LUAD. c, d The distribution of TMB and TNB between high- and low-SPRS patients in LUAD. e, f The distribution of MDSC and CAF between high- and low-SPRS patients in LUAD. g Survival analysis combined SPRS with TMB, TNB, MDSC, and CAFs in LUAD patients. LUAD lung adenocarcinoma, SPRS Scissor+ proliferating cell risk score, CAFs cancer-associated fibroblasts, MDSCs myeloid-derived suppressor cells, TMB tumor mutational burden, TNB tumor neoantigen burden; *p < 0.05, **p < 0.01, ***p < 0.001, ns not significant.

Back to article page